Abiopharma

HEARTBEAM, INC. (BEAT)

Symbol	BEAT
Name	HEARTBEAM, INC.
Sector	HEALTH CARE
Region	North America
Industry	Medical/Dental Instruments
Address	2118 WALSH AVENUE,SUITE 210, SANTA CLARA, California, 95050, United States
Telephone	+1 -408 899-4443
Fax	—
Email	—
Website	https://www.heartbeam.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	—
Description	HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first ever cable-free device capable of collecting ECG signals in 3D, from 3 non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care-all outside of a medical facility, thus redefining the future of cardiac health management. Additional info from NASDAQ: HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first ever cable-free device capable of collecting ECG signals in 3D, from 3 non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care-all outside of a medical facility, thus redefining the future of cardiac health management.

2026-04-17 00:48

Cruickshank Tim 🟢 acquired 31.2K shares of HeartBeam, Inc. (BEAT) at $0.80 Transaction Date: Apr 16, 2026 | Filing ID: 044841

2026-04-17 00:48

Director Elfrink Willem 🟢 acquired 187.5K shares of HeartBeam, Inc. (BEAT) at $0.80 Transaction Date: Apr 16, 2026 | Filing ID: 044840

2026-04-17 00:47

Director JAFF MICHAEL R 🟢 acquired 31.2K shares of HeartBeam, Inc. (BEAT) at $0.80 Transaction Date: Apr 16, 2026 | Filing ID: 044838

2026-04-17 00:47

Director Vajdic Branislav 🟢 acquired 31.2K shares of HeartBeam, Inc. (BEAT) at $0.80 Transaction Date: Apr 16, 2026 | Filing ID: 044837

2026-04-17 00:47

Director Ferrari Richard 🟢 acquired 62.5K shares of HeartBeam, Inc. (BEAT) at $0.80 Transaction Date: Apr 16, 2026 | Filing ID: 044835

2026-04-17 00:47

ENO Robert Paul 🟢 acquired 12.5K shares of HeartBeam, Inc. (BEAT) at $0.80 Transaction Date: Apr 16, 2026 | Filing ID: 044834

2026-04-17 00:46

Director Ortigas-Wedekind Marga 🟢 acquired 25.0K shares of HeartBeam, Inc. (BEAT) at $0.80 Transaction Date: Apr 16, 2026 | Filing ID: 044833

2026-04-17 00:46

Director STROME MARK E 🟢 acquired 750.0K shares of HeartBeam, Inc. (BEAT) at $0.80 Transaction Date: Apr 16, 2026 | Filing ID: 044832

2026-04-16 20:48

(99% Neutral) HEARTBEAM, INC. (BEAT) Announces Regulatory Update

2026-04-16 20:05

HeartBeam Announces Closing of $10 Million Public Offering of Common Stock

No clinical trials found for this company.

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
Vectorcardiography (VECG)	DEVICE	Approved	Arrhythmias, Cardiac	COMPLETED	NCT06123130

Total products: 1